Portage Biotech Inc. (PTGEF) 0.1100 $PTGEF
Portage's Biohaven Issued Notice of Allowance: Glutamate Agents in the Treatment of Mental Disorders
PR Newswire - Mon May 05, 1:00PM CDT
Intellectual property licensed from Yale University protects the use of certain glutamate modulating agents in the treatment of Generalized Anxiety Disorder
Portage provides updates
PR Newswire - Thu Apr 10, 3:00PM CDT
Portage Biotech Inc. ("Portage"
(OTCQB: PTGEF, CNSX: PBT.U) is pleased to provide the following update on the recent experimental work completed on the Antennapedia protein (ANTP) and additional transporter proteins by its wholly owned subsidiary, Portage Pharmaceuticals Ltd. ("PPL" or the "Company".
Critical Outcome Technologies Identifies Experienced Partner for Clinical Development of COTI-2
Marketwire - Wed Feb 26, 8:31AM CST
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that it has signed a non-binding letter of intent ("LOI" to form a joint venture with Portage Biotech Inc. ("Portage", a British Virgin Island incorporated public company, listed and traded on the Canadian Securities Exchange ("PTB.U", and on NASDAQ and the OTC ("PTGEF" to fund and direct the Phase 1 development of the Company's clinical oncology candidate, COTI-2.
Portage reports third quarter financial results and provides updates
PR Newswire - Tue Feb 25, 12:06PM CST
Portage Biotech Inc. ("Portage" (OTCQB: PTGEF, CNSX: PBT.U), today filed its unaudited consolidated financials and related management discussion & analysis for the three and nine months ended December 31, 2013. These can be viewed on our website, www.portagebiotech.com.
Portage acquires majority interest in Biohaven Pharmaceutical Holding Company Limited
PR Newswire - Mon Jan 06, 4:00PM CST
Portage Biotech Inc. ("Portage" (OTCQB: PTGEF, CNSX: PBT.U), is pleased to announce that it has acquired approximately 54% equity in Biohaven Pharmaceutical Holding Company Limited ("Biohaven", a private corporation formed under the laws of the British Virgin Islands, for $3.5 million, payable as $1.75 million upfront and the balance in three installments over the next eleven months.
Portage launches new website and provides update on its R&D Activities
PR Newswire - Tue Dec 17, 8:28AM CST
Portage Biotech Inc. ("the Company" (OTCQB: PTGEF, CNSX: PBT.U) ("Portage" is pleased to announce the launch of its new web site, www.portagebiotech.com, which goes live today.
Portage appoints Scientific Advisory Board
PR Newswire - Tue Nov 12, 11:03AM CST
Portage Biotech Inc. ("the Company" (OTCBB: PTGEF, CNSX: PBT.U), ("Portage" is pleased to announce that its wholly owned operating subsidiary, Portage Pharmaceuticals Ltd. ("PPL" has formed a Scientific Advisory Board ("SAB" to provide guidance and expertise as Portage develops proprietary biologically active peptides that utilize its licensed Antennapedia cell-permeable peptide technology that enables delivery to intracellular and intranuclear targets.
Portage's Biohaven Issued Notice of Allowance: Glutamate Agents in the Treatment of Mental Disorders
PR Newswire - Mon May 05, 1:00PM CDT
Intellectual property licensed from Yale University protects the use of certain glutamate modulating agents in the treatment of Generalized Anxiety Disorder
Portage provides updates
PR Newswire - Thu Apr 10, 3:00PM CDT
Portage Biotech Inc. ("Portage"
(OTCQB: PTGEF, CNSX: PBT.U) is pleased to provide the following update on the recent experimental work completed on the Antennapedia protein (ANTP) and additional transporter proteins by its wholly owned subsidiary, Portage Pharmaceuticals Ltd. ("PPL" or the "Company". Critical Outcome Technologies Identifies Experienced Partner for Clinical Development of COTI-2
Marketwire - Wed Feb 26, 8:31AM CST
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that it has signed a non-binding letter of intent ("LOI" to form a joint venture with Portage Biotech Inc. ("Portage", a British Virgin Island incorporated public company, listed and traded on the Canadian Securities Exchange ("PTB.U", and on NASDAQ and the OTC ("PTGEF" to fund and direct the Phase 1 development of the Company's clinical oncology candidate, COTI-2. Portage reports third quarter financial results and provides updates
PR Newswire - Tue Feb 25, 12:06PM CST
Portage Biotech Inc. ("Portage"
(OTCQB: PTGEF, CNSX: PBT.U), today filed its unaudited consolidated financials and related management discussion & analysis for the three and nine months ended December 31, 2013. These can be viewed on our website, www.portagebiotech.com. Portage acquires majority interest in Biohaven Pharmaceutical Holding Company Limited
PR Newswire - Mon Jan 06, 4:00PM CST
Portage Biotech Inc. ("Portage"
(OTCQB: PTGEF, CNSX: PBT.U), is pleased to announce that it has acquired approximately 54% equity in Biohaven Pharmaceutical Holding Company Limited ("Biohaven", a private corporation formed under the laws of the British Virgin Islands, for $3.5 million, payable as $1.75 million upfront and the balance in three installments over the next eleven months. Portage launches new website and provides update on its R&D Activities
PR Newswire - Tue Dec 17, 8:28AM CST
Portage Biotech Inc. ("the Company"
(OTCQB: PTGEF, CNSX: PBT.U) ("Portage" is pleased to announce the launch of its new web site, www.portagebiotech.com, which goes live today. Portage appoints Scientific Advisory Board
PR Newswire - Tue Nov 12, 11:03AM CST
Portage Biotech Inc. ("the Company"
(OTCBB: PTGEF, CNSX: PBT.U), ("Portage" is pleased to announce that its wholly owned operating subsidiary, Portage Pharmaceuticals Ltd. ("PPL" has formed a Scientific Advisory Board ("SAB" to provide guidance and expertise as Portage develops proprietary biologically active peptides that utilize its licensed Antennapedia cell-permeable peptide technology that enables delivery to intracellular and intranuclear targets. 
